An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction

被引：10
|
作者：
Macphee, CH
Nelson, JJ
机构：
[1] GlaxoSmithKline, Dept Vasc Biol, King Of Prussia, PA 19406 USA
[2] GlaxoSmithKline, Dept World Epidemiol, Res Triangle Pk, NC 27709 USA
来源：
EUROPEAN HEART JOURNAL | 2005年 / 26卷 / 02期
关键词：
D O I：
10.1093/eurheartj/ehi042
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：107 / 109
页数：3
相关论文
共 50 条
  • [21] Lipoprotein-associated phospholipase A2
    McConnell, Joseph P.
    Hoefner, Daniel M.
    CLINICS IN LABORATORY MEDICINE, 2006, 26 (03) : 679 - +
  • [22] Lipoprotein and Lipoprotein-associated Phospholipase A2 as Atherosclerosis Risk Factors (oxLDL) in Men with Central Obesity
    Sari, Nelly
    Wijaya, Andi
    Patellongi, Ilhamjaya
    INDONESIAN BIOMEDICAL JOURNAL, 2011, 3 (01): : 51 - 56
  • [23] Translational Studies of Lipoprotein-Associated Phospholipase A2 in Inflammation and Atherosclerosis
    Ferguson, Jane F.
    Hinkle, Christine C.
    Mehta, Nehal N.
    Bagheri, Roshanak
    DerOhannessian, Stephanie L.
    Shah, Rhia
    Mucksavage, Megan I.
    Bradfield, Jonathan P.
    Hakonarson, Hakon
    Wang, Xuexia
    Master, Stephen R.
    Rader, Daniel J.
    Li, Mingyao
    Reilly, Muredach P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (08) : 764 - 772
  • [24] Predicting the Risk of Cardiovascular DiseaseWhere Does Lipoprotein-Associated Phospholipase A2 Fit In?
    Natalie Khuseyinova
    Wolfgang Koenig
    Molecular Diagnosis & Therapy, 2007, 11 : 203 - 217
  • [25] Lipoprotein-associated phospholipase A2 and cardiovascular risk -: State of the evidence and future directions
    Iribarren, C
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (01) : 5 - 6
  • [26] Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target
    Ali, Muzammil
    Madjid, Mohammad
    FUTURE CARDIOLOGY, 2009, 5 (02) : 159 - 173
  • [27] Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation
    Chen, Jialing
    Zhang, Huisheng
    Chen, Wenwen
    CLINICA CHIMICA ACTA, 2019, 488 : 143 - 149
  • [28] Lipoprotein-associated phospholipase A2 and the risk of ischemic stroke
    Danihel, L.
    Madarasz, S.
    Blazicek, P.
    Lacko, A.
    Luha, J.
    Lehotska, V
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2018, 81 (03) : 308 - 313
  • [29] Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular diseases
    Siekmeier, Ruediger
    Grammer, Tanja B.
    Scharnagl, Hubert
    Stojakovic, Tatjana
    Koenig, Wolfgang
    Maerz, Winfried
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2010, 34 (04): : 217 - 222
  • [30] Lipoprotein-associated phospholipase A2:: A risk marker or a risk factor?
    Lerman, Amir
    McConnell, Joseph P.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A): : 11F - 22F
12345